Likewise, this value is in line with prior studies assessing combination therapies for patients with PD-1–naïve melanoma, including PD-1 nivolumab combined with LAG-3 inhibitor relatlimab (43.1%, RELATIVITY-047) and nivolumab combined with CTLA-4 inhibitor ipilimumab (57.6%, CheckMate-067; refs. 4, 5). Here, PDCD1 is linked to melanoma.